About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Cd19tm1(cre/ERT2)Rsky
targeted mutation 1, Klaus Rajewsky
MGI:5614310
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre/ERT2)Rsky/Cd19+ 		involves: 129P2/OlaHsd * C57BL/6J MGI:5614487
cn2
 		Cd19tm1(cre/ERT2)Rsky/Cd19+
Myd88em1.1Rsky/Myd88+ 		involves: 129P2/OlaHsd * C57BL/6NTac MGI:7281485


Genotype
MGI:5614487
cn1
Allelic
Composition		 Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre/ERT2)Rsky/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre/ERT2)Rsky mutation (1 available); any Cd19 mutation (56 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation (0 available); any Gt(ROSA)26Sor mutation (942 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
enlarged spleen ( J:217520 )
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
increased B cell number ( J:217520 )
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
increased CD4-positive, alpha-beta T cell number ( J:217520 )
• massive expansion in tamoxifen-treated mice
increased CD8-positive, alpha-beta T cell number ( J:217520 )
• massive expansion in tamoxifen-treated mice
increased activated T cell number ( J:217520 )
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
abnormal T cell physiology ( J:217520 )
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

hematopoietic system
enlarged spleen ( J:217520 )
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
increased B cell number ( J:217520 )
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
increased CD4-positive, alpha-beta T cell number ( J:217520 )
• massive expansion in tamoxifen-treated mice
increased CD8-positive, alpha-beta T cell number ( J:217520 )
• massive expansion in tamoxifen-treated mice
increased activated T cell number ( J:217520 )
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
abnormal T cell physiology ( J:217520 )
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro

growth/size/body
enlarged spleen ( J:217520 )
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice




Genotype
MGI:7281485
cn2
Allelic
Composition		 Cd19tm1(cre/ERT2)Rsky/Cd19+
Myd88em1.1Rsky/Myd88+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre/ERT2)Rsky mutation (1 available); any Cd19 mutation (56 available)
Myd88em1.1Rsky mutation (0 available); any Myd88 mutation (50 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
increased plasma cell number ( J:308792 )
• 15x increase in spleen 10 days after tamoxifen tre
• persistently high number of IgM+ plasma cells in spleen and bone marrow for at least 70 weeks after tamoxifen treatment
increased IgM level ( J:308792 )
• high total IgM serum levels for at least 70 weeks after tamoxifen treatment, displaying discrete paraprotein bands in the gamma-globulin zone upon serum protein electrophoresis

immune system
increased plasma cell number ( J:308792 )
• 15x increase in spleen 10 days after tamoxifen tre
• persistently high number of IgM+ plasma cells in spleen and bone marrow for at least 70 weeks after tamoxifen treatment
increased IgM level ( J:308792 )
• high total IgM serum levels for at least 70 weeks after tamoxifen treatment, displaying discrete paraprotein bands in the gamma-globulin zone upon serum protein electrophoresis

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
monoclonal gammopathy of uncertain significance DOID:7442 J:308792




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory